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Abstract 
Background: Experimenter’s allegiance (EA) refers to a personal confidence of the superiority of a specific psycho-
therapy treatment. This factor has been linked with larger treatment effects in favor of the preferred treatment. How-
ever, various studies have displayed contradictory results between EA and the pattern of treatment effects.
Aims: Using a systematic approach followed by meta-analysis, we aimed to evaluate the impact of an allegiance 
effect on the results of psychotherapeutic studies.
Method: We considered the meta-analyses of randomized controlled trials (RCTs) of different types of psychothera-
pies in the Cochrane Database of Systematic Reviews. Eligible articles included meta-analyses of RCTs with at least 
one study showing evidence of EA (i.e., allegiant study). Effect sizes in allegiant RCTs were compared with non-alle-
giant using random and fixed models and a summary relative odds ratio (ROR) were calculated. Heterogeneity was 
quantified with the I2 metric.
Results: A total of 30 meta-analyses including 240 RCTs were analyzed. The summary ROR was 1.31 [(95 % con-
fidence interval (CI: 1.03–1.66) P = 0.30, I2 = 53 %] indicating larger effects when allegiance exists. The impact of 
allegiance did not differ significantly (P > 0.05) when we compared psychiatric versus medical outcomes. Allegiance 
effect was significant for all forms of psychotherapy except for cognitive behavioral therapy. Moreover, the impact of 
allegiance was significant only when the treatment integrity of delivered psychotherapy was not assessed. Allegiance 
effect was even stronger where the experimenter was also both the developer of the preferred treatment and super-
vised or trained the therapists. No significant differences were found between allegiant and non-allegiant studies in 
terms of overall quality of studies.
Conclusions: Experimenter’s allegiance influences the effect sizes of psychotherapy RCTs and can be considered 
non-financial conflict of interest introducing a form of optimism bias, especially since blinding is problematic in this 
kind of research. A clear reporting of EA in every single study should be given an opportunity to investigators of mini-
mizing its overestimation effects.
Keywords: Allegiance effect, Experimenter’s allegiance, Psychotherapy, Optimism bias, Non-financial conflict of 
interest, Systematic bias
© 2015 Dragioti et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Allegiance in psychotherapy represents the therapist’s 
personal belief both in the superiority and the efficacy of 
a particular treatment [1–4]. Practicing therapists tend 
to choose a psychotherapy approach which is compatible 
with their beliefs and experience [2]. There is a hypoth-
esis that the treatment effect can be larger when the 
therapist has proposed and developed the particular psy-
chotherapy and/or supervised the therapist(s) applying 
it [4–6]. In psychotherapy research double-blind designs 
cannot be performed and therefore such experimenter 
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biases are very difficult to be addressed [1–5, 7]. As a 
result, allegiance is a common factor existing across psy-
chotherapy treatments that can influence the results of a 
conducted study [2–4].
The role of “therapeutic allegiance of the experi-
menter” [4] on psychotherapy research is a major con-
cern and a long-standing debate has taken place [1, 2, 4, 
5, 7]. Many investigators argue that experimenter’s alle-
giance (EA) can introduce systematic bias suggesting an 
adjustment in results of these studies in order to mini-
mize the impact of allegiance [1, 8]. Sources of how EA 
could affect the outcome comprise poor training of ther-
apists, the enthusiasm of the investigator for a particular 
treatment, the phenomenon of negative or null findings 
remain unpublished and the potential selection of biased 
therapists holding allegiances in crossed therapist study 
designs [1, 9]. However, others consider allegiance as a 
reflection of real differences between treatment compar-
isons (i.e., a better performance in treatment delivery of 
the preferred treatment) [1, 10, 11] recommending that 
adjustment for allegiance would lead to erroneous con-
clusions [10].
To date there is no sufficient evidence either to sup-
port or reject these arguments. Despite the fact that 
many researchers found that the outcomes of psycho-
therapies are influenced from allegiance to a specific 
school of thought [1, 4, 7, 12–14], the role of allegiance 
in the research field should be evaluated cautiously [1, 
5, 15, 16]. Several meta-analyses have shown contradic-
tory results between EA and treatment effect sizes in 
favor of the preferred treatment. For example, Miller 
et  al. [17] in a meta-analysis regarding various child-
hood disorders found that the effect of allegiance on 
the variation of the true effects in the unconditional 
model reached 100  %. In contrast, other meta-analy-
ses did not support that allegiance has an obvious and 
consolidated effect on the results of psychotherapeutic 
studies [15, 16]. Two further studies assessing EA as a 
primary outcome have also reported conflicting results 
[18, 19]. Briefly, Gaffan et  al., found that the existing 
correlation among EA and treatment effect in cognitive 
therapy (CT) setting was not substantial [18]. Recently, 
Munder et  al. advocated the hypothesis of bias result-
ing from methodological weaknesses in treatment com-
parisons [19].
In this work we aimed to systematically assess the 
potential influence of EA on a wide spectrum of psy-
chotherapies and disorders comparing the magnitude of 
the effect sizes on allegiant vs. non-allegiant studies. To 
that end, we studied psychotherapy treatments included 
in meta-analyses of randomized controlled trials (RCTs) 
that have been published in Cochrane Library.
Methods
Search strategy and selection of reviews
We retrieved, from a previously published database that 
systematically assessed meta-analyses of RCTs for all 
types of psychotherapy and for various psychiatric and 
medical outcomes [20], all meta-analyses that included 
at least one RCT with clear evidence of EA. All studies 
were included in the Cochrane Database of Systematic 
Reviews (CDSR; Issue 9, 2010). We used only meta-anal-
yses from the CDSR in order to eliminate the possibility 
of multiple recording of EA within meta-analyses on the 
same topic.
Specifically, we included meta-analyses with at least 
one study where one or more of the co-authors had 
developed the treatment or both developed the treat-
ment and trained the therapists or both developed the 
treatment and supervised the therapists or supervised 
and/or trained the therapists alone. We included all 
studies where a certain type of psychotherapy treatment 
(authentic or not [21, 22]) for a wide range of medical and 
psychiatric disorders was directly compared with a non-
experimental control arm (e.g., waiting list, usual care, 
standard care, no intervention and placebo). Meta-anal-
yses that compare any psychotherapy treatment vs. medi-
cation or other alternative treatment as control group 
were also included. Meta-analyses with studies regarding 
study designs other than RCTs were excluded. Whenever 
a meta-analysis assessed the same outcome, we kept the 
version of the article that included the larger number of 
studies. No participant’s age restrictions were applied.
We did not include meta-analyses that examined a 
combination of psychotherapy and non-psychotherapy 
treatments (e.g., medication) if it was directly compared 
with another type of psychotherapy or meta-analyses 
evaluating direct comparisons between different types 
of psychotherapy. Meta-analyses assessing non-verbal 
techniques, web-based treatments and non-specific or 
miscellaneous treatments (e.g., yoga, dietary advice, rec-
reation, biofeedback, etc.) were also excluded.
Data extraction
From each eligible meta-analysis we recorded Cochrane 
ID, first author, publication year, diagnostic categories, 
number of analysis, control/comparison arms, number 
of RCTs of psychotherapy treatments included in meta-
analysis, primary outcome investigated, type of data 
(continuous, dichotomous), the total number of partici-
pants, number of participants in comparison and con-
trol arm, the effect size (ES) of each study [standardized 
mean difference (SMD) or odds ratio (OR)] and its 95 % 
confidence intervals (CI). For each review, we extracted 
information on the main outcomes as they were reported 
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by the Cochrane reviews. If the main outcome was 
not eligible, we recorded the secondary outcome that 
included the most studies in each meta-analysis. When-
ever a systematic review was providing multiple com-
parisons, we recorded only the analysis that compared a 
psychotherapy with a non-experimental control arm. We 
followed the actual definition of each Cochrane review in 
order to categorize the type of psychotherapy treatments, 
i.e., cognitive behavioral therapy (CBT), psychoanalytic 
informed psychotherapies (PIPs), family systems therapy 
(FST), etc.
For each RCT included in the meta-analysis, we also 
recorded the existence of EA (Y/N), number of authors 
with allegiance, authentic approaches (also called bona 
fide treatment [21, 22] Y/N/Unclear), treatment integrity 
assessment (Y/N) and different levels of EA (e.g., devel-
oped the therapy or supervised or trained the therapists). 
We finally recorded the position of the “allegiant author” 
in the authorship list (first/last author vs. other position). 
In addition, data for risk of bias were extracted, accord-
ing to the evaluation reported by the Cochrane reviews 
using the following domains of the risk of bias tool of the 
Cochrane Collaboration [23, 24]: methods for sequence 
generation and allocation concealment, blinding, and 
incomplete outcome data. Then for each single study the 
overall quality was classified as high (that is, low risk of 
bias for all domains), moderate (that is, unclear risk of 
bias for one or more domains in the absence of high risk 
of bias and low (that is, high risk of bias for one or more 
domains). Finally, we determined the quality of the deliv-
ered psychotherapy treatment according to the following 
criteria proposed by Furukawa et al. [25]: (A) high, when 
the psychotherapy alone arm was shown to be superior to 
the placebo arm in the same trial or when the same group 
of investigators had proved effectiveness in a separate 
randomized controlled trial; (B) moderate, when the con-
duct of psychotherapy was examined by a third reviewer 
through audiotapes, etc.; and (C) low, when the authors 
gave sufficiently detailed descriptions of the psychother-
apy procedure.
One author (ED) examined the abstract of each of the 
identified references so as to evaluate the relevance of the 
meta-analytic studies. Whenever a study was eligible for 
inclusion, the full article was retrieved and two authors 
(ED, EE) extracted the data independently and they 
reached consensus in case of inconsistencies.
Methods of rating the experimenter’s allegiance 
in included RCTs
Every single included RCT in eligible meta-analyses was 
independently reviewed by two investigators (ED, EE) for 
evidence of EA. The investigators reviewed the sections 
of introduction, method and reference list blind to results 
so as to assess whether one or more authors of the pri-
mary study were allegiant to the considered psychother-
apy. We used a two-step process to code allegiance. We 
first rated evidence of allegiance in a continuum concept 
according to a six-point scale (from 0 to 5) proposed by 
Wampold et al. [26]. Then, we assigned an absolute alle-
giance rating of 1 (any level of EA = 1–5 in continuum 
concept) and 0 (no level of EA = 0 in continuum concept) 
for each psychotherapy treatment of the included RCTs 
[20]. We used the same distinction followed by Shadish 
and Montgomery [27] in order to create two groups of 
included RCTs (allegiant vs. non-allegiant) that would be 
feasible to be compared according to our study design.
Analysis
To harmonize all the available information and allow for 
the synthesis of the evidence, we performed a transfor-
mation of the SMD to a logOR, whenever continuous 
data were available. This is based on the assumption that 
an underlying continuous variable produces a logistic 
distribution of equal standard deviation in the two inter-
vention groups [28, 29].
From each comparison we obtained the summary OR 
for the allegiant studies (ORA) and the non-allegiant 
(ORNA) within the eligible meta-analyses using fixed 
effects models [30]. Then, we obtained a relative OR 
(ROR) from the comparison of ORA vs. ORNA for each 
eligible meta-analysis. A ROR which exceeds 1 equates 
to assessments that provide a more favorable response to 
the experimental treatment when a co-author is affiliated 
(e.g., developed the therapy, supervised or trained the 
therapists, etc.) to the psychotherapy under study com-
pared to studies where non-experimenter’s allegiance is 
present.
To obtain a summary ROR across the meta-analyses, 
we combined the natural logarithm estimates of the 
RORs among all comparisons [31] using fixed and ran-
dom effects [32]. Heterogeneity was evaluated with 
Cochran’s Q statistic (statistically significant for P < 0.10) 
and it was quantified with the I2 metric [33] (low, mod-
erate, large, very large for values of <25, 25–49, 50–74, 
>75  %, respectively). When heterogeneity is absent 
(I2 = 0), random and fixed effects coincide.
All eligible comparisons were considered for the main 
analysis. A subgroup analysis was also performed accord-
ing to the outcome (psychiatric disorders vs. other medi-
cal disorders), to the types of psychotherapy (e.g., CBT, 
PIPs, FST) and according to the type of data (binary vs. 
continuous). We also carried out sensitivity analyses lim-
ited in meta-analysis concerning bona fide treatments, 
treatment integrity, overall quality of study, overall 
quality of psychotherapy treatment, and ranking in the 
authorship list. We also performed a sensitivity analysis 
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by level of allegiance. Specifically we created three groups 
where authors that have developed or trained or super-
vised the therapy correspond to the previously described 
rate of 5; the group where the author has developed the 
therapy corresponds to a rate of 4; and all other to rates 
1–3. We have grouped the last category in order to have 
adequate power to analyze the results. Analyses were 
performed in STATA 10.0 (STATA Corp., College Sta-
tion, TX, USA). P values are two tailed.
Meta‑regression
In order to examine further the potential sources of 
heterogeneity, a random effect meta-regression analy-
sis was performed [34]. In this analysis we included the 
outcome, the type of psychotherapy, the type of the out-
come (binary/continuous), the treatment integrity assess-




From a previously published database that included 146 
meta-analyses, we used the 60 systematic reviews from 
the CDSR [20]. These reviews were scrutinized further 
in depth for eligibility. Of these, we excluded 19 reviews 
because they did not meet our inclusion criteria and 41 
were deemed eligible. In two out of 41 eligible meta-
analyses, we were not able to clearly identify allegiance of 
any of the co-authors in the eligible RCTs and in 9 studies 
allegiance was present in all included RCTs and therefore 
they were excluded since we could not estimate a ROR for 
those meta-analyses. We finally included 30 reviews that 
met all the aforementioned inclusion criteria (see Addi-
tional file  1). The two independent researchers reached 
a very high level of agreement (216/240 studies) and in 
all cases (coding of allegiance or other disagreements in 
data extraction was discussed with a third researcher and 
a consensus was reached).
Characteristics of eligible reviews
The thirty eligible meta-analyses (see Additional file  2) 
synthesized data from 240 RCTs, of which 18 (60  %) 
assessed binary and 12 (40  %) assessed continuous out-
comes. Each meta-analysis included a median of 6 studies 
[interquantile range (IQR) 5–9] and a median of 4 studies 
with evidence of allegiance (IQR 3–5). The median num-
ber of participants per meta-analysis was 493 (IQR 239–
803). The majority of meta-analyses (63.3  %) compared 
the efficacy or effectiveness of cognitive behavioral ther-
apy versus control (n  =  19). The outcome under study 
was various anxiety disorders (n = 6, 20.0 %), depression 
(n  =  4, 13.3  %) and chronic pain (n  =  4, 13.3  %). Six-
teen meta-analyses assessed another outcome. Table  1 
shows in detail the characteristics of included Cochrane 
reviews.
Comparison of RORs
The summary ROR (sROR) was 1.31 (95 % CI 1.03–1.66, 
P =  0.030) using random effects model and 1.32 (95  % 
CI 1.14–1.52, P = 1.4 × 10−4 by fixed effects. Moderate 
heterogeneity was observed (I2  =  53  %) (Fig.  1). In 18 
meta-analyses, the summary ROR was >1 showing that 
the experimental treatment was more favorable in stud-
ies where allegiance was present. Four out of those 18 
Table 1 Characteristics of eligible meta-analyses (m-a)
IQR interquartile range
Characteristic; n (%), unless otherwise stated Value
Number of eligible m-a 30 (100)
Number of included studies per m-a; median (IQR)
 Total 6 (5–9)
 With ≥1 allegiance 4 (3–5)
 With no allegiance 2 (1–4)
Sample size; median (IQR) 493 (239–803)
Meta-analysis favors
 Experimental arm 20 (66.7)
 No significant difference 10 (33.3)
Type of data:
 Binary 18 (60.0)
 Continuous 12 (40.0)
Types of psychotherapy:
 Cognitive behavior therapy (CBT) 19 (63.3)
 Behavioral therapy (BT) 2 (6.7)
 Family systems therapy (FST) 1 (3.3)
 Psychological debriefing 1 (3.3)
 Psychoanalytically informed psychotherapies (PIPs) 1 (3.3)
 Supportive or counseling therapy 3 (10.5)
 Variants of CBT 3 (10.5)
Outcomes:
 Anxiety disorders 6 (20.0)
 Depression 4 (13.3)
 Chronic pain 4 (13.3)
 Eating disorders 2 (6.7)
 Personality disorders 2 (6.7)
 Substance use disorders 2 (6.7)
 Smoking cessation 2 (6.7)
 Asthma 1 (3.3)
 Chronic fatigue syndrome 1 (3.3)
 Common mental disorders 1 (3.3)
 Mental illness and substance disorders 1 (3.3)
 Schizophrenia 1 (3.3)
 Tinnitus 1 (3.3)
 Hypertension 1 (3.3)
 Miscellaneous conditions (behavioral problems) 1 (3.3)
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studies were significant. In 12 meta-analyses the effect 
was in favor of non-allegiant studies and two out of those 
were significant.
Subgroup analyses using fixed and random effects are 
summarized in Table  2. Specifically, no significant differ-
ence was observed using random effects models regarding 
the outcome (psychiatric disorders vs. medical disorders) 
and type of data (binary vs. continuous). When we exam-
ined the effect of different types of psychotherapy trea-
ments, we found that CBT had a sROR = 1.07 [(95 % CI 
0.85–1.34), P = 0.580, I2 = 19 %]. For supportive or coun-
seling therapy sROR = 1.44 [(95 % CI 1.01–2.05), P = 0.046, 
I2  =  0  %], whereas for other forms of psychotherapy 
sROR = 2.35 [(95 % CI 1.10–4.99), P = 0.027, I2 = 79 %].
Sensitivity analysis
In a sensitivity analysis where we considered the position 
of the allegiance experimenter in the authorship list the 
sROR was 1.58 [(95 % CI 1.00–2.47) P = 0.048, I2 = 64 %] 
when the allegiant author was placed in another author-
ship position rather than the first or last and 1.25 [(95 % 
CI 1.00–1.56) P  =  0.047, I2  =  35  %] when the author 
was first or last, using random effects model (Table  3). 
Regarding the various evidence of allegiance, the sROR 
was favorable for studies where the experimenter had 
developed the therapy with sROR = 1.36 [(95 % CI 1.07–
1.72), P = 0.011, I2 = 49 %]. The magnitude of the effect 
was stronger in cases where the experimenter had both 
developed the therapy and supervised the therapists that 
conducted the treatment with sROR  =  2.39 [(95  % CI 
1.15–4.99), P = 0.020, I2 = 65 %], but it was attenuated or 
even disappeared in the other levels of EA such as train-
ing or supervision alone. In analysis of the bona fide treat-
ments vs. non-bona fide vs. unclear bona fide treatments 
a significant allegiance effect in favor of non-bona fide 
treatments was found: sROR = 2.51 [(95 % CI 1.01–6.23), 
P  =  0.048 and I2  =  88  %]. The analysis addressing the 
quality of studies did not show any significant association 
Fig. 1 ROR and 95 % confidence intervals (CIs) for each comparison of an “allegiant” vs. “non-allegiant study”. The summary ROR has been calculated 
with random effects model. A ROR >1 favors allegiance; a ROR <1 favors non-allegiance
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between allegiant and non-allegiant studies, whereas sig-
nificant differences were observed in cases where treat-
ment integrity was not evaluated (sROR  =  1.54 [(95  % 
CI 1.01–2.35), P  =  0.047 and I2  =  74  %]. Finally, the 
magnitude of the effect was stronger only in the case of 
low quality of the delivered psychotherapy sROR = 1.61 
[(95 % CI 1.00–2.59), P = 0.049 and I2 = 76 %], as shown 
in Table 3.
Meta‑regression
A meta-regression including the aforementioned vari-
ables revealed that only the assessment of treatment 
Table 2 Summary RORs in various subgroup analyses
ROR relative odds ratio
Characteristic No of studies Summary ROR (95 % CI)
fixed effects
P Summary ROR (95 % CI)
random effects
P I2 (%)
Overall 30 1.32 (1.14–1.52) 1.4 × 10−4 1.31 (1.03–1.66) 0.030 53
Outcome
 Psychiatric disorders 20 1.37 (1.14–1.62) 5.4 × 10−4 1.30 (0.92–1.66) 0.143 64
 Medical disorders 10 1.24 (0.97–1.57) 0.085 1.24 (0.97–1.84) 0.085 0
Types of psychotherapy
 CBT 22 1.10 (0.92–1.31) 0.311 1.07 (0.85–1.34) 0.580 19
 Supportive or counseling 3 1.44 (1.01–2.05) 0.046 1.44 (1.01–2.05) 0.046 0
 Other 5 2.22 (1.62–3.05) 8.7 × 10−7 2.35 (1.10–4.99) 0.027 79
Type of data
 Binary 18 1.50 (1.21–1.85) 2.2 × 10−4 1.39 (0.94–2.05) 0.097 21
 Continuous 12 1.19 (0.99–1.44) 0.069 1.19 (0.93–1.51) 0.164 62
Table 3 Summary RORs in sensitivity analysis for specific characteristics
N number of studies that the comparison under study exists, ROR relative odds ratio
Characteristic N Summary ROR (95 % CI)
fixed effects




 First/last position 30 1.26 (1.07–1.47) 0.005 1.25 (1.00–1.56) 0.047 35
 Other position 20 1.53 (1.22–1.92) 2.5 × 10−4 1.58 (1.00–2.47) 0.048 64
Continuum level of allegiance
 Developed and supervised or trained (5) 6 2.22 (1.56–3.17) 1.2 × 10−5 2.39 (1.15–4.99) 0.020 65
 Developed the therapy (4) 30 1.36 (1.18–1.57) 3.4 × 10−5 1.36 (1.07–1.72) 0.011 49
 Other (1–3) 8 0.60 (0.38–0.96) 0.035 0.64 (0.31–1.30) 0.217 45
Bona fide treatment
 Yes 14 0.99 (0.79–1.24) 0.940 0.94 (0.68–1.29) 0.709 42
 No 10 1.68 (1.27–2.22) 2.8 × 10−4 2.51 (1.01–6.23) 0.048 88
 Unclear 4 1.97 (0.57–6.76) 0.280 1.06 (0.97–1.16) 0.173 0
Quality of studies
 High quality 15 1.28 (1.04–1.50) 0.021 1.54 (0.87–2.74) 0.141 78
 Moderate quality 22 1.46 (1.12–1.89) 0.005 1.20 (0.73–1.99) 0.467 66
 Low quality 7 0.41 (0.22–0.77) 0.041 0.53 (0.18–1.58) 0.257 54
Treatment integrity assessment
 Yes 9 1.05 (0.79–1.39) 0.763 0.99 (0.62–1.56) 0.952 53
 No 28 1.29 (1.07–1.55) 0.007 1.54 (1.01–2.35) 0.047 74
Quality of psychotherapy
 High quality (A) 6 1.01 (0.66–1.55) 0.973 1.48 (0.91–2.42) 0.120 57
 Unclear quality (B) 6 1.38 (0.84–2.28) 0.205 1.28 (0.49–3.30) 0.612 53
 Low quality (C) 27 1.28 (1.05–1.56) 0.014 1.61 (1.00–2.59) 0.049 76
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integrity was significantly contributing to the heteroge-
neity of sROR (regression coefficient = 0.56, P = 0.042) 
(see Additional file 3).
Discussion
We evaluated RCTs of psychotherapy treatments 
included in 30 eligible meta-analyses and we have shown 
that there is an inflation of the reported effect when EA 
is present. Specifically, reported effect sizes were found 
to be larger by almost 30 % when the allegiant therapist 
had participated in the respective RCT compared to 
studies in which he was not included in the authorship 
list. Moderate heterogeneity was observed; however, this 
is well expected given the wide range of treatments and 
outcomes assessed in the analysis [35, 36].
To our knowledge, this is the first study that quanti-
fies the observed effect and investigates the allegiance 
phenomenon in such a systematic manner across a 
spectrum of different psychotherapy treatments and 
outcomes. Other studies that tried to examine the experi-
menter allegiance hypothesis, focused only on specific 
psychotherapies or outcomes [5, 15–19, 26]. In our ini-
tial screening, we found that 1 out of 4 identified meta-
analyses included only allegiant studies and from the 30 
eligible meta-analyses almost 60 % of the primary studies 
included an investigator with evidence of allegiance as a 
co-author. It is evident that allegiance is present in a large 
number of RCTs of psychotherapy treatments, and there-
fore it should be carefully assessed and evaluated.
One may argue that the observed difference is not a 
biased inflation of the treatment effect, but could reflect 
the fact that the treatment offered by the therapist that 
developed the psychotherapy is simply superior to the 
treatment offered by other investigators [1, 10, 11]. 
However, we found that the inflation was not statisti-
cally significant when we limited our analysis in studies 
where authors have assessed the integrity of the deliv-
ered psychotherapy treatment. This could imply that EA 
may influence outcomes by affecting treatment adher-
ence and competence [37]. This finding is consistent with 
the hypothesis that “therapist attitudes and openness” 
towards a particular treatment are likely to influence 
treatment integrity [38, 39], given that only the partici-
pants are blind to which treatment they receive [2, 5]. 
Therefore, it can be suggested that EA may act as system-
atic bias [2, 5, 19, 40] similar to optimism bias [41] rather 
than as a true efficacy effect [1, 10, 11] at least when the 
integrity of the psychotherapy is not evaluated. Opti-
mism bias have been defined as an unwarranted belief 
in the efficacy of new treatments and a major overesti-
mation factor that affecting RCTs [41]. This type of bias 
may be explained by the potential conflict between an 
experimenter’s allegiance to a school of thought and can 
be considered as a non-financial conflict of interest (COI) 
[42].
We also found that the EA effect is larger in supportive, 
counseling or other methods that include psychodynamic 
and family systems therapy. In contrast, even though an 
almost 10 % inflation was observed in CBT approach this 
effect was not significant. This could imply that CBT-
related RCTs are well designed and the investigators have 
gained experience and methodological expertise due to 
training over the years, even though in our analysis there 
was no difference between the type of the psychother-
apy and the quality of the study. Previous study by Gaf-
fan et al. has argued that allegiance effect in CBT studies 
was more intense in earlier years but decreased over 
time [18]. Given that CBT is ranked at the highest level 
of empirical evidence compared to other types of psy-
chotherapies in the literature [43], someone may argue 
that optimism bias can be observed in specific and new 
empirically supported approaches of psychotherapy. The 
latter is also supported by work of Luborsky et al. [5]. Of 
course, due to small number of comparisons, this result 
must be evaluated with caution.
Moreover, we found that the psychotherapy treatment 
effects are rather inflated when the experimenter both 
developed and supervised or trained the delivered ther-
apy compared to other levels of allegiance. This finding 
is in accordance with other studies that found an associa-
tion between level of allegiance and effect size [17]. One 
possible explanation is that the developers of specific 
psychotherapy treatments show more interest for the 
evidence-based practice of their own therapies compared 
to others [42]. Along with the fact that investigators’ psy-
chotherapy preferences tend to produce more positive 
results [44] experimenter’s allegiance effect may inflate 
the relative efficacy of various psychotherapies in a famil-
iar manner that COI impacts on the relative efficacy of 
the various drug trials [42]. COI(s) have been defined as 
a set of conditions in which professional judgment con-
cerning a primary interest (e.g., patient welfare, research 
validity) may be unduly influenced by a secondary inter-
est (e.g., personal recognition, career advancement or vis-
ibility in the media; bestowing favor on a relative, friend 
or colleague; the allegiance to a school of thought) [45]. 
Many investigators have found that industry sponsorship 
trials are more likely to have favorable outcomes (e.g., 
efficacy or safety) than independently financed drug trial 
[46–49]. It has been shown that odds of positive results 
are more that twofold larger when COI exists, which is 
comparable with our findings here [48].
We also found a significant inflation in non-bona fide 
treatments (non-authentic) in contrast to bona fide 
(authentic) and unclear bona fide treatments. This find-
ing indicates that absence of investigators treatment 
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integrity may allow allegiance to interfere, therefore it 
could be considered as one of the potential sources of 
allegiance bias [37]. Moreover, low quality of the deliv-
ered psychotherapy may also include a plausible rationale 
for the allegiance effect. Other factors such as the ranking 
of the investigators in the authorship list and the quality 
of the study design do not seem to significantly contrib-
ute to this effect.
There are some caveats to the findings of this meta-
epidemiological study. First, we did not explore the 
potential interaction of the authors of the non-allegiant 
studies with the “allegiant therapist”. It is possible that 
some authors or even the leading author could be a for-
mer trainee, a student or even a colleague of the “alle-
giant” scientist. Therefore, he might be equally well 
trained for the application of the specific psychotherapy 
treatment. However, it is expected that this would lead 
to an underestimation of our effects rather than to the 
observed inflation. Similarly, we did not explore the pos-
sibility that more than one author were coded as EA. We 
have inadequate power perform such an analysis, due the 
very low number of comparisons given that <6 and <1 % 
of the studies had two or three allegiant authors, respec-
tively. Finally, we based our evaluation only on the lim-
ited information available in the published articles and 
therefore may we have not identified all allegiant studies. 
However, other studies that have identified links between 
allegiance and psychotherapeutic studies results have 
similarly relied upon identical sources and types to meas-
ure allegiance. [15–19, 26, 27]
Conclusions
In this study, we show that experimenter’s allegiance 
effect inflates the reported effect sizes in randomized 
controlled trials in psychotherapy by 30  %. This treat-
ment effect could be attributed to different components 
such as the superiority of the treatment given by an expe-
rienced therapist that proposed the intervention. How-
ever, a distinct component could arise due to systematic 
biases and affect the reported effects in a way similar to 
conflict of interest observed in medical research litera-
ture. Therefore, even though this is a non-financial con-
flict of interest, we strongly suggest that experimenter’s 
allegiance should be clearly reported in every single rand-
omized controlled trial and meta-analysis of psychother-
apeutic treatments. This becomes apparent as our group 
has shown that allegiance is seldom reported in RCTs 
and meta-analyses [20]. Adequate documentation will 
allow for the assessment of the possible allegiance in each 
study and will also provide the opportunity to the investi-
gators to control for allegiance using previously proposed 
techniques [1, 2, 5, 12, 13, 17–19, 50].
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